1. Home
  2. CINGW vs MATV Comparison

CINGW vs MATV Comparison

Compare CINGW & MATV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CINGW
  • MATV
  • Stock Information
  • Founded
  • CINGW N/A
  • MATV 1995
  • Country
  • CINGW United States
  • MATV United States
  • Employees
  • CINGW 13
  • MATV N/A
  • Industry
  • CINGW Biotechnology: Pharmaceutical Preparations
  • MATV Paper
  • Sector
  • CINGW Health Care
  • MATV Basic Materials
  • Exchange
  • CINGW Nasdaq
  • MATV Nasdaq
  • Market Cap
  • CINGW N/A
  • MATV N/A
  • IPO Year
  • CINGW 2021
  • MATV 1995
  • Fundamental
  • Price
  • CINGW $0.04
  • MATV $4.96
  • Analyst Decision
  • CINGW
  • MATV Strong Buy
  • Analyst Count
  • CINGW 0
  • MATV 1
  • Target Price
  • CINGW N/A
  • MATV $10.00
  • AVG Volume (30 Days)
  • CINGW N/A
  • MATV 815.0K
  • Earning Date
  • CINGW N/A
  • MATV 05-07-2025
  • Dividend Yield
  • CINGW N/A
  • MATV 8.06%
  • EPS Growth
  • CINGW N/A
  • MATV N/A
  • EPS
  • CINGW N/A
  • MATV N/A
  • Revenue
  • CINGW N/A
  • MATV $1,981,100,000.00
  • Revenue This Year
  • CINGW N/A
  • MATV $1.00
  • Revenue Next Year
  • CINGW N/A
  • MATV $2.60
  • P/E Ratio
  • CINGW N/A
  • MATV N/A
  • Revenue Growth
  • CINGW N/A
  • MATV N/A
  • 52 Week Low
  • CINGW N/A
  • MATV $4.34
  • 52 Week High
  • CINGW N/A
  • MATV $19.96
  • Technical
  • Relative Strength Index (RSI)
  • CINGW N/A
  • MATV 39.81
  • Support Level
  • CINGW N/A
  • MATV $4.45
  • Resistance Level
  • CINGW N/A
  • MATV $4.83
  • Average True Range (ATR)
  • CINGW 0.00
  • MATV 0.44
  • MACD
  • CINGW 0.00
  • MATV 0.05
  • Stochastic Oscillator
  • CINGW 0.00
  • MATV 36.39

About CINGW Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: